Sepsis detection in hematologic and solid tumor malignancies using quantitative inflammatory biomarker differences in...

Area of Science:

• Oncology
• Infectious Diseases
• Immunology

Background:

• Sepsis, a life-threatening response to infection, poses a higher risk for cancer patients.
• Blood cultures have limitations, especially in culture-negative sepsis, necessitating reliable serological biomarkers.
• Distinguishing sepsis in malignancy patients requires understanding unique immune responses.

Purpose of the Study:

• To evaluate the efficacy of serological biomarkers in diagnosing sepsis in patients with hematologic and solid tumors.
• To compare the diagnostic performance of biomarkers between hematologic and solid cancer sepsis cases.
• To identify cancer-specific diagnostic strategies for sepsis.

Main Methods:

• Prospective observational study design.
• Analysis of serological biomarkers including C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), white blood cells (WBC), lymphocytes (LYM), neutrophils (NEU), and monocytes (MON).
• Evaluation of biomarker efficacy in distinguishing sepsis in patients with hematologic versus solid tumors.

Main Results:

• Hematologic cancer patients with sepsis showed significantly elevated IL-6, PCT, and MON levels (AUC > 0.75).
• Solid tumor patients with sepsis had a moderate, non-significant increase in PCT (AUC = 0.693).
• Biomarker combinations improved diagnostic power for hematologic cancers but showed limited efficacy in solid tumors.

Conclusions:

• IL-6, PCT, and MON are valuable biomarkers for sepsis detection in hematologic malignancies.
• Current biomarkers have limited efficacy in diagnosing sepsis in solid tumors.
• Cancer-specific diagnostic approaches are crucial, considering the distinct immune dynamics in hematologic versus solid tumors.